| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-09-11 19:52:00 UTC |
|---|
| Updated at | 2022-09-11 19:52:00 UTC |
|---|
| NP-MRD ID | NP0319036 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | levomethadyl acetate |
|---|
| Description | Levomethadyl Acetate, also known as LAAM or levacetylmethadolum, belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. It also acts as a potent, noncompetitive α3β4 neuronal nicotinic acetylcholine receptor antagonist. Unlike methadone, which requires daily administration, LAAM is administered two to three times a week. Levomethadyl Acetate is a drug which is used for the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients. It has a melting point of 215 °C and a molecular weight of 353.50. Levomethadyl Acetate is a very strong basic compound (based on its pKa). Levomethadyl acetate can be converted into nor-levomethadyl acetate and formaldehyde through its interaction with the enzyme cytochrome P450 3A7. In humans, levomethadyl acetate is involved in levomethadyl acetate metabolism pathway. In 2001, LAAM was removed from the European market due to reports of life-threatening ventricular rhythm disorders. Levomethadyl Acetate is a potentially toxic compound. levomethadyl acetate is found in Apis cerana. levomethadyl acetate was first documented in 2000 (PMID: 11058673). LAAM is indicated as a second-line treatment for the treatment and management of opioid dependence if patients fail to respond to drugs like methadone or buprenorphine (PMID: 12220607) (PMID: 12646332) (PMID: 15104241) (PMID: 12676878). |
|---|
| Structure | CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-alpha-Acetylmethadol | ChEBI | | (1S,4S)-4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate | ChEBI | | 1-alpha-Acetylmethadol | ChEBI | | LAAM | ChEBI | | Levacetilmetadol | ChEBI | | Levacetylmethadolum | ChEBI | | Levomethadyl | ChEBI | | Orlaam | ChEBI | | Levacetylmethadol | Kegg | | (-)-a-Acetylmethadol | Generator | | (-)-Α-acetylmethadol | Generator | | (1S,4S)-4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetic acid | Generator | | 1-a-Acetylmethadol | Generator | | 1-Α-acetylmethadol | Generator | | Levomethadyl acetic acid | Generator | | Levo-alphacetylmethadol | HMDB | | Levo-methadyl acetate | HMDB | | Nor-laam | HMDB | | Levo-alpha-acetylmethadol | HMDB | | Levomethadyl acetate hydrochloride | HMDB | | (3R,6R)-3-Acetoxy-6-dimethylamino-4,4-diphenylheptane | HMDB | | Dimepheptanol | HMDB | | 6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate | HMDB | | Alphacetylmethadol | HMDB | | Levoacetylmethadol | HMDB | | Methadol | HMDB | | Acetylmethadol | HMDB | | Amidolacetate | HMDB | | Acemethadone | HMDB | | Levo alpha acetylmethadol | HMDB | | Methadyl acetate | HMDB |
|
|---|
| Chemical Formula | C23H31NO2 |
|---|
| Average Mass | 353.4977 Da |
|---|
| Monoisotopic Mass | 353.23548 Da |
|---|
| IUPAC Name | (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl acetate |
|---|
| Traditional Name | levomethadyl acetate |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1 |
|---|
| InChI Key | XBMIVRRWGCYBTQ-AVRDEDQJSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Diphenylmethanes |
|---|
| Direct Parent | Diphenylmethanes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Diphenylmethane
- Aralkylamine
- Amino acid or derivatives
- Carboxylic acid ester
- Tertiary aliphatic amine
- Tertiary amine
- Carboxylic acid derivative
- Monocarboxylic acid or derivatives
- Amine
- Organooxygen compound
- Organonitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Carbonyl group
- Organic nitrogen compound
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000 Nov 2;343(18):1290-7. doi: 10.1056/NEJM200011023431802. [PubMed:11058673 ]
- Kreek MJ, Vocci FJ: History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat. 2002 Sep;23(2):93-105. doi: 10.1016/s0740-5472(02)00259-3. [PubMed:12220607 ]
- Kuo I, Brady J, Butler C, Schwartz R, Brooner R, Vlahov D, Strathdee SA: Feasibility of referring drug users from a needle exchange program into an addiction treatment program: experience with a mobile treatment van and LAAM maintenance. J Subst Abuse Treat. 2003 Jan;24(1):67-74. doi: 10.1016/s0740-5472(02)00343-4. [PubMed:12646332 ]
- Deshmukh SV, Nanovskaya TN, Hankins GD, Ahmed MS: N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92. doi: 10.1016/j.bcp.2003.10.007. [PubMed:15104241 ]
- Nanovskaya TN, Deshmukh SV, Miles R, Burmaster S, Ahmed MS: Transfer of L-alpha-acetylmethadol (LAAM) and L-alpha-acetyl-N-normethadol (norLAAM) by the perfused human placental lobule. J Pharmacol Exp Ther. 2003 Jul;306(1):205-12. doi: 10.1124/jpet.103.050690. Epub 2003 Apr 3. [PubMed:12676878 ]
- LOTUS database [Link]
|
|---|